

Anis A Hamid

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5838477/publications.pdf>

Version: 2024-02-01

32
papers

537
citations

1040056

9
h-index

677142

22
g-index

32
all docs

32
docs citations

32
times ranked

1282
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 199-207.	3.9	3
2	Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 713-719.	3.9	17
3	Association between CD8 and PD-L1 expression and outcomes after radical prostatectomy for localized prostate cancer. <i>Prostate</i> , 2021, 81, 50-57.	2.3	22
4	EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. <i>Nature Cancer</i> , 2021, 2, 444-456.	13.2	118
5	NF- κ B Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants. <i>Molecular Cancer Research</i> , 2021, 19, 1137-1145.	3.4	9
6	Testicular seminoma metastases presenting as gastrointestinal malignancy: A case report and review of the literature. <i>ANZ Journal of Surgery</i> , 2021, , .	0.7	0
7	Biological and therapeutic advances in the pursuit of effective immunotherapy for prostate cancer. <i>Current Opinion in Urology</i> , 2020, 30, 30-35.	1.8	3
8	Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1322-1331.	1.6	23
9	Impact of baseline serum IL-8 on metastatic hormone-sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805). <i>Prostate</i> , 2020, 80, 1429-1437.	2.3	11
10	Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study. , 2020, 8, e000538.		19
11	Luminal B subtype as a predictive biomarker of docetaxel benefit for newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A correlative study of E3805 CHAARTED.. <i>Journal of Clinical Oncology</i> , 2020, 38, 162-162.	1.6	16
12	Impact of baseline serum IL-8 on metastatic hormone-sensitive (mHSPC) prostate cancer outcomes in the phase III CHAARTED trial (E3805).. <i>Journal of Clinical Oncology</i> , 2020, 38, 171-171.	1.6	1
13	Response to olaparib or carboplatin in a real-world cohort of men with DNA damage repair (DDR) deficient metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 43-43.	1.6	3
14	Tumor infiltrating lymphocytes (TIL) assessment in muscle invasive bladder cancer (MIBC) patients treated with cisplatin-based neoadjuvant chemotherapy (NAC) and surgery.. <i>Journal of Clinical Oncology</i> , 2020, 38, 547-547.	1.6	1
15	Causes and patterns of mortality in patients with lethal germ cell tumor (GCT).. <i>Journal of Clinical Oncology</i> , 2020, 38, 421-421.	1.6	0
16	Prevalence and clinical impact of BRCA1/2 mutations in patients with de novo metastatic hormone-sensitive prostate cancer (mHSPC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 44-44.	1.6	1
17	Benefit of prophylactic anticoagulation before and during first-line chemotherapy on patients with metastatic germ cell tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 402-402.	1.6	0
18	Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy. <i>European Urology Oncology</i> , 2019, 2, 475-482.	5.4	17

#	ARTICLE	IF	CITATIONS
19	Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (<i>CHEK2</i>) With Susceptibility to Testicular Germ Cell Tumors. <i>JAMA Oncology</i> , 2019, 5, 514.	7.1	43
20	Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer. <i>European Urology</i> , 2019, 76, 89-97.	1.9	158
21	Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 420-427.	3.9	49
22	Clinical Trials of Metastatic Castration-sensitive Prostate Cancer: Recent Progress and New Horizons. <i>European Urology Focus</i> , 2019, 5, 165-167.	3.1	2
23	Autologous Stem-Cell Transplantation Outcomes for Relapsed Metastatic Germ-Cell Tumors in the Modern Era. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 58-64.e1.	1.9	7
24	Risk of febrile neutropenia and early treatment cessation in men receiving standard and dose-reduced 3-weekly docetaxel for metastatic castration-resistant prostate cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, e399-e404.	1.1	4
25	Communicating prognosis of patients with advanced cancer between health care providers: a tertiary cancer center review of written correspondence. <i>Annals of Palliative Medicine</i> , 2018, 7, 404-410.	1.2	5
26	Association of low PTEN expression by fluorescence immunohistochemistry (F-IHC) and lethal disease in men with surgically-treated prostate cancer (PrCa).. <i>Journal of Clinical Oncology</i> , 2018, 36, 15-15.	1.6	1
27	Tumor suppressor aberrations and outcomes in localized and metastatic hormone sensitive prostate cancer (PrCa).. <i>Journal of Clinical Oncology</i> , 2018, 36, 184-184.	1.6	0
28	Impact of new systemic therapies on overall survival (OS) of patients (pts) with metastatic castration resistant prostate cancer (mCRPC) in a hospital-based registry.. <i>Journal of Clinical Oncology</i> , 2018, 36, 203-203.	1.6	0
29	DNA damage and repair (DDR) gene variants and outcomes in localized and metastatic prostate cancer (mPC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 304-304.	1.6	0
30	Delayed PSA responses in metastatic castration resistant prostate cancer (mCRPC) patients (pts) treated with sipuleucel-T.. <i>Journal of Clinical Oncology</i> , 2018, 36, e17041-e17041.	1.6	0
31	Clinical outcomes with cumulative tumor suppressor gene (TSG) alterations in castration sensitive (CSPC) and resistant (CRPC) prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5055-5055.	1.6	0
32	A new standard-of-care for advanced-stage disease. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 592-593.	27.6	4